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Open access una b s t r a c t
Ethnopharmacological relevance: Several species of Eugenia L. are used in folk medicine for the treatment
of various diseases. Eugenia brasiliensis is used for the treatment of inﬂammatory diseases, whereas
Eugenia. uniﬂora is used for the treatment of symptoms related to depression and mood disorders, and is
used in Brazil by the Guarani Indians as a tonic stimulant.
Aim of the study: To investigate the antidepressant-like effect of hydroalcoholic extracts of different
plant species of genus Eugenia and to characterize the participation of the monoaminergic systems in the
mechanism of action of the specie that afforded the most prominent antidepressant-like efﬁcacy.
Materials and methods: In the ﬁrst set of experiments, the effects of hydroalcoholic extracts of Eugenia
beaurepaireana, Eugenia brasiliensis, Eugenia catharinae, Eugenia umbelliﬂora and Eugenia uniﬂora and the
antidepressant ﬂuoxetine (positive control) administered acutely by p.o. route were evaluated in the tail
suspension test (TST) and locomotor activity was assessed in the open-ﬁeld test in mice. In the second
set of experiments, the involvement of the monoaminergic systems in the antidepressant-like activity of
Eugenia brasiliensis was evaluated by treating mice with several pharmacological agonists and
antagonists. The effects of the combined administration of sub-effective doses of Eugenia brasiliensis
and the antidepressants ﬂuoxetine, imipramine and bupropion were also evaluated.
Results: The administration of the extracts from Eugenia brasiliensis, Eugenia catharinae and Eugenia
umbelliﬂora, but not Eugenia beaurepaireana and Eugenia uniﬂora, exerted a signiﬁcant antidepressant-like
effect, without altering locomotor activity. The behavioral proﬁle was similar to ﬂuoxetine. Pre-treatment
of mice with ketanserin, haloperidol, SCH23390, sulpiride, prazosin and yohimbine prevented the
reduction of immobility time induced by Eugenia brasiliensis. Treatment with sub-effective doses of
WAY100635, SKF38393, apomorphine, phenylephrine, but not clonidine, combined with a sub-effective
dose of Eugenia brasiliensis decreased the immobility time in the TST. Furthermore, the combined
administration of sub-effectives doses of Eugenia brasiliensis with ﬂuoxetine, imipramine and bupropion
produced an antidepressant-like effect.
Conclusions: This study show, for the ﬁrst time, the antidepressant-like effect of species of the genus
Eugenia, especially Eugenia brasiliensis, whose effects in the TST seem to be mediated by serotoninergic
(5-HT1A and 5-HT2 receptors), noradrenergic (a1-adrenoceptor) and dopaminergic (dopamine D1 and D2
receptors) systems.
& 2012 Elsevier Ireland Ltd. Open access under the Elsevier OA license., dimethylsulfoxide;
ase A; SNRIs, serotonin and
otonin reuptake inhibitor;
ax: þ55 48 3721 9672.
der the Elsevier OA license.1. Introduction
Depression is a common disorder usually associated with sub-
stantial symptom severity and disability that is projected by the
World Health Organization as the leading cause disease burden for
the year 2030 (Kessler et al., 2003; Le´pine and Briley, 2011). Many
studies reveal important roles for monoaminergic systems in the
pathophysiology and treatment of depression (Coppen, 1967;
Elhwuegi, 2004; Schildkraut, 1965). However, the treatment of
depression with conventional antidepressants (monoamine oxidase
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tive noradrenaline reuptake inhibitors) provides a complete remis-
sion just for 50% of the patients (Nestler et al., 2002; Rush et al.,
2003) and produces side effects that may reduce the adhesion of
patients to treatment (Brunello et al., 2002; MacGillivray et al.,
2003; Sleath et al., 2003).
The use of alternative therapies is highly sought by patients
with depression, especially the use of herbal medicines (Kessler
et al., 2001; Tachil et al., 2007). Thus, developing safe and
effective agents from traditional herbs may provide a good way
to lessen the side effects as well as to improve the efﬁcacy of
conventional treatment (Wang et al., 2008).
The plants of the genus Eugenia L. (Myrtaceae) are used in folk
medicine for the treatment of various diseases such as arthritis,
rheumatism and diabetes (Revilla, 2002). Eugenia uniﬂora L. is
used in folk medicine for the treatment of symptoms related to
depression and mood disorders, likely nervousness, anxiety and
irritation (Alves et al., 2008; Franco and Fontana, 2004; Greinger,
1996; Korbes, 1995), and is used in Brazil by the Guarani Indians
as a tonic stimulant (Alonso, 1998). However, there are no studies
regarding the possible antidepressant-like action of this or other
species of the genus Eugenia.
Therefore, the aim of this study was ﬁrst to investigate the
effects of the hydroalcoholic extracts from Eugenia beaurepaireana
(Kiaersk.) D.Legrand, Eugenia brasiliensis Lam., Eugenia catharinae
O.Berg, Eugenia umbelliﬂora O.Berg, and Eugenia uniﬂora L. in the
tail suspension test, a predictive test of antidepressant activity. In a
second set of experiments, this study investigated the possible
involvement of the monoaminergic systems in the antidepressant-
like effect of the hydroalcoholic extract from Eugenia brasiliensis in
the TST. Furthermore, the effects of the combined administration of
sub-effective doses of Eugenia brasiliensis and antidepressants from
different classes (the serotonin reuptake inhibitor ﬂuoxetine, the
tricyclic antidepressant imipramine and the dopamine reuptake
inhibitor bupropion) were evaluated.2. Methods
2.1. Plant material and preparation of the hydroalcoholic extracts
Eugenia beaurepaireana and Eugenia brasiliensis were collected
in Santo Amaro da Imperatriz, Eugenia catharinae on Daniela
beach, Eugenia umbelliﬂora and Eugenia uniﬂora in Floriano´polis
(Santa Catarina State, Brazil). The identiﬁcation was performed
by botanist Dr. Daniel de Barcellos Falkenberg and a voucher
specimen was deposited in the Herbarium of the Department of
Botany, Federal University of Santa Catarina (UFSC), Brazil (Euge-
nia beaurepaireana—34.675, Eugenia brasiliensis—34.674, Eugenia
catharinae—27.820, Eugenia umbelliﬂora—17.890 and Eugenia
uniﬂora—23.152).
The dried and powdered leaves (100 g) of different species of
Eugenia were extracted three times by maceration with 96%
ethanol for 7 day at room temperature. After extraction, the
alcoholic extracts were ﬁltered and the procedure was repeated
twice. The resulting extracts were dried and concentrated in
rotary evaporator under reduced pressure (60 1C), resulting in
8.97 g, 10.82 g, 15.56 g, 8.18 g and 19.20 g of crude extract of
Eugenia beaurepaireana, Eugenia brasiliensis, Eugenia catharinae,
Eugenia umbelliﬂora and Eugenia uniﬂora, respectively.
2.2. Animals
Swiss mice (35–45 g) of either sex (homogeneously distributed
among groups) were maintained at constant room temperature
(21–23 1C) with free access to water and food, under a 12:12 hlight:dark cycle (lights on at 07:00 h). Mice were allowed to
acclimatize to the holding room for 24 h before the behavioral
procedure. All manipulations were conducted in the light phase,
with each animal used only once (n¼7–8 animals per group).
All procedures were performed in accordance with the National
Institute of Health Guide for the Care and Use of Laboratory
Animals and approved by the Ethics Committee of the Institution.
All efforts were made to minimize animals suffering and to reduce
the number of animals used in the experiments.
2.3. Drugs and treatment
The hydroalcoholic extracts and ﬂuoxetine (10 mg/kg, p.o.,
positive control) were dissolved in distilled water with 10%
Tween 80 and administered acutely by oral route (p.o.) 60 min
before the TST or open-ﬁeld test. A control group received
distilled water with 10% Tween 80 as vehicle.
The following drugs were used: ketanserin, N-[2-[4-(2-methox-
yphenyl)-1-piperazinyl]ethyl]-N-(2-pyridyl) cyclohexanecarboxa-
mide (WAY100635), haloperidol, R-(þ)-7-chloro-8-hydroxy-3
methyl-1-phenyl-2,3,4,5-tetrahydro-1H-3-benzazepine hydrochlor-
ide (SCH23390), sulpiride, (7)-1-phenyl-2,3,4,5-tetrahydro-1H-3-
benzazepine-7,8-diol hydrochloride (SKF38393), apomorphine,
prazosin, yohimbine, phenylephrine, clonidine and ﬂuoxetine
(all from Sigma Chemical Company, St. Louis,MO, U.S.A.) All drugs
were administered by intraperitoneal (i.p.) route, except ﬂuoxetine
that was administered by oral route and WAY100534, SCH23390,
SKF38393 and phenylephrine that were administered by subcuta-
neous (s.c.) route. All drugs were administered in a constant volume
of 10 ml/kg body weight. Drugs were dissolved in saline, except
sulpiride that was diluted in saline with 5% DMSO and ﬂuoxetine
that was diluted in distilled water. Control animals received
appropriate vehicle.
In the experiments designed to study the time-course effect of
the hydroalcoholic extract of Eugenia brasiliensis (1 mg/kg, p.o.),
the immobility time in the TST was assessed in an independent
group of mice, 30, 60 or 120 min after the administration of the
extract.
In order to address some of the mechanisms by which the
extract of Eugenia brasiliensis causes antidepressant-like action in
the TST, mice were treated with different pharmacological agents.
A possible contribution of the serotonergic system (5-HT
receptor subtypes) in the antidepressant-like effect of the extract
of Eugenia brasiliensis in the TST was investigated by pre-treating
mice with a sub-effective dose of the extract of Eugenia brasiliensis
(0.1 mg/kg, p.o.) or vehicle. After 30 min they received a sub-
effective dose of WAY100635 (0.1 mg/kg, s.c.) or vehicle before
being tested in the TST 30 min later. In a separate set of
experiments, animals were pre-treated with ketanserin (5 mg/kg,
i.p., a preferential 5-HT2A receptor antagonist), or vehicle and
after 30 min, they received the extract of Eugenia brasiliensis
(1 mg/kg, p.o.) or vehicle before being tested in the TST 60 min
later (Freitas et al., 2010).
In order to investigate the possible involvement of the nora-
drenergic system in the antidepressant-like effect of the extract of
Eugenia brasiliensis in the TST, animals were pre-treated with
prazosin (1 mg/kg, i.p., an a1-adrenoceptor antagonist), yohimbine
(1 mg/kg, i.p., an a2-adrenoceptor antagonist), or vehicle and after
30 min they received the extract of Eugenia brasiliensis (1 mg/kg,
p.o.) or vehicle before being tested in the TST 60 min later. In a
separate set of experiments, in order to investigate a possible
synergistic effect between the extract of Eugenia brasiliensis and
noradrenergic agonists, animals were pre-treated with a sub-
effective dose of the extract of Eugenia brasiliensis (0.1 mg/kg,
p.o.) or vehicle and after 30 min they received a sub-effective dose
of phenylephrine (5 mg/kg, s.c., an a1-adrenoceptor agonist),
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before being tested in the TST 30 min later (Capra et al., 2010;
Freitas et al., 2010; Machado et al., 2007).
We also investigate the inﬂuence of the dopaminergic system
in the antidepressant-like effect of the extract of Eugenia
brasiliensis in the TST. Mice were pre-treated with haloperidol
(0.2 mg/kg, i.p., a nonselective dopaminergic receptor antagonist),
SCH23390 (0.05 mg/kg, s.c., a dopamine D1 receptor antagonist),
sulpiride (50 mg/kg, i.p., a dopamine D2 receptor antagonist) or
vehicle, and after 30 min they received the extract of Eugenia
brasiliensis (1 mg/kg, p.o.) or vehicle and were tested in the TST
60 min later. In order to investigate a possible synergistic effect
between the extract of Eugenia brasiliensis and dopaminergic
agonists, mice were pre-treated with a sub-effective dose of the
extract of Eugenia brasiliensis (0.1 mg/kg, p.o.) or vehicle and
after 30 min they received a sub-effective dose of SKF38393
(0.1 mg/kg, s.c., a dopamine D1 receptor agonist), apomorphine
(0.5 mg/kg, i.p., a dopamine D2 receptor agonist) or vehicle before
being tested in the TST 30 min later (Binfare´ et al., 2009, 2010;
Capra et al., 2010; Freitas et al., 2010; Machado et al., 2007, 2009).
In another experiment, the effect of the combined administra-
tion of a sub-effective dose of the extract of Eugenia brasiliensis
(0.1 mg/kg) with sub-effective doses of antidepressants ﬂuoxetine
(5 mg/kg), imipramine (0.1 mg/kg) and bupropion (1 mg/kg) in
the TST or open-ﬁeld test was investigated. To this end, mice
received extract or vehicle and immediately after, the antidepres-
sant or vehicle was administered. Sixty minutes later, the TST or
open-ﬁeld test was carried out.
The administration schedule and the doses of the drugs used
were chosen based on experiments previously performed in our
laboratory and literature data conﬁrm the efﬁcacy of the above
mentioned protocols (Binfare´ et al., 2009, 2010; Brocardo et al.,
2008; Capra et al., 2010; Dhingra and Valecha, 2007; Freitas et al.,
2010; Kaster et al., 2007; Machado et al., 2007; 2009; O’Neill
et al., 2001).
2.4. Tail suspension test (TST)
The total duration of immobility induced by tail suspension
was measured according to the method previously described
(Steru et al., 1985). Mice both acoustically and visually isolated
were suspended 50 cm above the ﬂoor by adhesive tape placed
approximately 1 cm from the tip of the tail. Immobility time was
recorded during a 6-min period. Mice were considered immobile
only when they hung passively or stay completely motionless.
Conventional antidepressants decrease the immobility time in
this test (Cunha et al., 2008; Steru et al., 1985).
2.5. Open-ﬁeld test
To assess the possible effects of the hydroalcoholic extracts
from Eugenia species on locomotor activity, mice were evaluated
in the open-ﬁeld paradigm as previously described (Rodrigues
et al., 1996, 2002). Mice were individually placed in a wooden box
(406050 cm) with the ﬂoor divided into 12 squares. The
number of crossing in the squares with the four paws was
registered during a period of 6 min. The ﬂoor of the open-ﬁeld
apparatus was cleaned with 10% ethanol between tests.
2.6. Statistical analysis
All experimental results are given as the mean7S.E.M. Com-
parisons between experimental and control groups were per-
formed by one-way (dose-response curves and time-course
curve) or two-way ANOVA (study of the mechanism of action)followed by Newman Keuls test when appropriate. A value of
Po0.05 was considered to be signiﬁcant.3. Results
3.1. Effect of hydroalcoholic extracts of the species of the genus
Eugenia on the immobility time in the TST and locomotor activity
in the open-ﬁeld test
Fig. 1 shows the effects of the acute administration of Eugenia
beaurepaireana, Eugenia brasiliensis, Eugenia catharinae, Eugenia
umbelliﬂora and Eugenia uniﬂora by p.o. route in the TST in mice.
The one-way ANOVA revealed a signiﬁcant antidepressant-like
effect of hydroalcoholic extracts of Eugenia brasiliensis (Fig. 1B)
and Eugenia catharinae (Fig 1C) (1, 10 and 100 mg/kg), and
Eugenia umbelliﬂora (Fig. 1D) (10 and 100 mg/kg) in the TST.
However, Eugenia beaurepaireana and Eugenia uniﬂora adminis-
tration produced no signiﬁcant effect in the TST. Since Eugenia
brasiliensis produced the most signiﬁcant results with the
lowest effective dose (Po0.01 at the dose of 1 mg/kg, p.o.)
when compared with the other species tested, we investigate
the involvement of the monoaminergic systems in its antidepres-
sant-like effect.
Fig. 2 shows that the administration of the extracts (Eugenia
beaurepaireana, Eugenia brasiliensis, Eugenia catharinae, Eugenia
umbelliﬂora, and Eugenia uniﬂora) did not signiﬁcantly alter the
locomotor activity of mice in the open-ﬁeld test.
In order to investigate the interval time that the extract of
Eugenia brasiliensis achieves the best performance in the TST, a
time-response curve was carried out. Fig. 3 illustrates that the
extract of this plant (1 mg/kg, p.o.) produced an antidepressant-
like effect 60 min after its administration, but this effect was not
observed when the TST was carried out 30 or 120 min after the
administration of the extract. Considering these results, all
experiments were performed using 60 min as the time interval
between the administration of the extract and the TST.
3.2. Investigation of possible mechanisms underlying the
antidepressant-like effect of Eugenia brasiliensis in the TST
3.2.1. Involvement of the serotonergic system
The results presented in Fig. 4A shows that treatment with
WAY100635 (0.1 mg/kg, s.c., a selective 5-HT1A receptor antago-
nist) was effective to enhance the effect of a sub-effective dose of
Eugenia brasiliensis (0.1 mg/kg, p.o.) in the TST. Fig. 4B shows that
administration of WAY100635 itself or in combination with
extract did not affect the locomotor activity in the open-ﬁeld test.
The pre-treatment of animals with ketanserin (5 mg/kg, i.p., a
preferential 5-HT2A receptor antagonist) signiﬁcantly prevented
the reduction of immobility time induced by the administration
of an active dose of Eugenia brasiliensis (1 mg/kg, p.o.) in the TST
(Fig. 4C), without affecting locomotor activity in the open-ﬁeld
test (Fig. 4D).
3.2.2. Involvement of the noradrenergic system
The results presented in Fig. 5A shows that the pre-treatment
of mice with prazosin (1 mg/kg, i.p., a1-adrenoceptor antagonist)
was able to reverse the antidepressant-like effect of Eugenia
brasiliensis (1 mg/kg, p.o.) in the TST, without affecting locomotor
activity in the open-ﬁeld test (Fig. 5B). The pre-treatment of
animals with yohimbine (1 mg/kg, i.p., a2-adrenoceptor antago-
nist) was also able to prevent the antidepressant-like effect of
Eugenia brasiliensis (1 mg/kg, p.o.) in the TST (Fig. 5C), without
affecting the locomotor activity in the open-ﬁeld test (Fig. 5D).
Fig. 1. Effect of treatment with Eugenia beaurepaireana (A), Eugenia brasiliensis (B), Eugenia catharinae (C), Eugenia umbelliﬂora (D) and Eugenia uniﬂora (E) (p.o.), vehicle or
ﬂuoxetine in the TST in mice. Values are expressed as mean7S.E.M (n¼7–8). nPo0.05 and nnPo0.01 compared to animals treated with vehicle. (A) [F(4,35)¼3.66,
Po0.01]; (B) [F(5,42)¼7.81, Po0.01]; (C) [F(5,42)¼8.26, Po0.01]; (D) [F(4,35)¼5.56, Po0.01]; (E) [F(4,30)¼2.74, Po0.05].
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phenylephrine (5 mg/kg, s.c., a1-adrenoceptor agonist) poten-
tiated the effect of a sub-effective dose of Eugenia brasiliensis
(0.1 mg/kg, p.o.) in the TST, without affecting the locomotor
activity of animals in the open-ﬁeld test (Fig. 6B). Fig. 6C shows
that the treatment of mice with clonidine (0.06 mg/kg, i.p.,
a2-adrenoceptor agonist) was not able to potentiate the effect of
a sub-effective dose of Eugenia brasiliensis (0.1 mg/kg, p.o.) in the
TST and did not modify the locomotor activity in the open-ﬁeld
test (Fig. 6D).3.2.3. Involvement of the dopaminergic system
The results depicted in Fig. 7A show that the pre-treatment of
mice with haloperidol (0.2 mg/kg, i.p., non-selective dopamine
receptors antagonist) prevented the reduction of immobility timeinduced by the treatment of mice with an active dose of Eugenia
brasiliensis (1 mg/kg, p.o.) in the TST. No effect in the locomotor
activity in the open-ﬁeld test was observed (Fig. 7B). Fig. 7C
shows that the pre-treatment of mice with SCH23390 (0.05 mg/kg,
s.c., dopamine D1 receptor antagonist) prevented the reduction of
immobility time induced by Eugenia brasiliensis (1 mg/kg, p.o.) in
the TST, without affecting the locomotor activity of mice.
(Fig. 7D). Moreover, Fig. 7E shows that the pre-treatment of mice
with sulpiride (50 mg/kg, i.p., dopamine D2 receptor antagonist)
was effective in preventing the antidepressant-like effect of
Eugenia brasiliensis (1 mg/kg, p.o.) in the TST, but did not alter
the locomotor activity in the open-ﬁeld test (Fig. 7F).
The results presented in Fig. 8A show that treatment of
animals with a sub-effective dose of SKF 38393 (0.1 mg/kg, s.c.,
a dopamine D1 receptor agonist) potentiated the effect of a sub-
effective dose of Eugenia brasiliensis (0.1 mg/kg, p.o.) in the TST,
Fig. 3. Effect of an acute administration of the hydroalcoholic extract from Eugenia brasiliensis (1 mg/kg, p.o.) 30, 60 or 120 min before the TST (A), and in the open-ﬁeld
test (B). Each column represents the mean7S.E.M. (n¼8). nnPo0.01 as compared with the vehicle. (A) 30 min (F(1,14)¼2.39, P¼0.14]; 60 min [F(1,14)¼35.44, Po0.01];
120 min [F(1,14)¼0.33, P¼0.58]; (B) 30 min [F(1,14)¼0.01, P¼0.90]; 60 min [F(1,14)¼3.04, P¼0.10]; 120 min [F(1,14)¼1.66, P¼0.22].
Fig. 2. Effect of treatment with Eugenia beaurepaireana (A), Eugenia brasiliensis (B), Eugenia catharinae (C), Eugenia umbelliﬂora (D) and Eugenia uniﬂora (E) (p.o.), vehicle
or ﬂuoxetine in the open-ﬁeld test. Values are expressed as mean7S.E.M (n¼7–8). (A) [F(4,35)¼0.65, P¼0.63]; (B) [F(5,42)¼1.85, P¼0.12]; (C) [F(5,42)¼0.71, P¼0.62];
(D) [F(4,35)¼0.80, P¼0.53]; (E) [F(4,30)¼1.01, P¼0.42].
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treatment of animals with a sub-effective dose of apomorphine
(0.5 mg/kg, i.p., a dopamine D2 receptor agonist) potentiated theeffect of a sub-effective dose of Eugenia brasiliensis (0.1 mg/kg,
p.o.) in the TST (Fig. 8C), and did not modify the locomotor
activity in the open-ﬁeld test (Fig. 8D).
A.R.S. Colla et al. / Journal of Ethnopharmacology 143 (2012) 720–731 7253.3. Effect of the interaction of hydroalcoholic extract of Eugenia
brasiliensis with conventional antidepressants in the immobility time
in the TST, and locomotor activity in the open-ﬁeld test
The effect of combined administration of a sub-effective dose of
the SSRI ﬂuoxetine (5 mg/kg) and Eugenia brasiliensis (0.1 mg/kg) onFig. 5. Effect of pre-teatment with prazosin (1 mg/kg, i.p.) or yohimbine (1 mg/kg, i.p.)
open-ﬁeld test (B) and (D). Each column represents the mean7S.E.M (n¼8). nnPo0.0
brasiliensis group pre-treated with vehicle. (A) Pre-treatment [F(1,28)¼48.50, Po0.01
[F(1,28)¼17.14, Po0.01]; (B) Pre-treatment [F(1,28)¼0.01, P¼0.91], treatment [F(1
P¼0.56]; (C) Pre-treatment [F(1,28)¼17.98, Po0.01], treatment [F(1,28)¼9.44, Po0.0
treatment [F(1,28)¼3.11, P¼0.09], treatment [F(1,28)¼0.001, P¼0.97] and pre-treatm
Fig. 4. Effect of the combined treatment with a sub-effective dose of Eugenia brasiliensi
ﬁeld test (B). Effect of pre-teatment with ketanserin (5 mg/kg, i.p.) in the effect of E
Each column represents the mean7S.E.M (n¼8). nnPo0.01 compared with the vehicle
with vehicle. (A) Pre-treatment [F(1,28)¼13.75, Po0.01], treatment [F(1,28)¼1.88
(B) Pre-treatment [F(1,28)¼0.26, P¼0.62], treatment [F(1,28)¼0.32, P¼0.58] and pr
[F(1,28)¼18.45, Po0.01], treatment [F(1,28)¼15.30, Po0.01] and pre-treatment x tr
P¼0.32], treatment [F(1,28)¼0.94, P¼0.34], and pre-treatment x treatment interactiontotal duration of immobility time in mice are shown in Fig. 9A. This
combination signiﬁcantly decreased the immobility time as com-
pared to vehicle in the TST, without affecting the locomotor activity
in the open-ﬁeld test (Fig. 9B).
The tricyclic antidepressant imipramine administered at a sub-
effective dose (0.1 mg/kg, p.o.) produced a synergistic anti-immobilityin the effect of Eugenia brasiliensis (1 mg/kg, p.o.) in the TST (A and C), and in the
1 compared with the vehicle-treated control. Po0.01 as compared with Eugenia
], treatment [F(1,28)¼8.48, Po0.01] and pre-treatment x treatment interaction
,28)¼0.13, P¼0.72] and pre-treatment x treatment interaction [F(1,28)¼0.35,
1] and pre-treatment x treatment interaction [F(1,28)¼14.42, Po0.01]; (D) Pre-
ent x treatment interaction [F(1,28)¼0.02, P¼0.88].
s (0.1 mg/kg, p.o.) and WAY100635 (0.1 mg/kg, s.c.) in the TST (A) and in the open-
ugenia brasiliensis (1 mg/kg, p.o.) in the TST (C), and in the open-ﬁeld test (D).
-treated control. Po0.01 as compared with Eugenia brasiliensis group pre-treated
, P¼0.18] and pre-treatment x treatment interaction [F(1,28)¼8.18, Po0.01];
e-treatment x treatment interaction [F(1,28)¼2.04, P¼0.16]; (C) Pre-treatment
eatment interaction [F(1,28)¼13.34, Po0.01]; (D) Pre-treatment [F(1,28)¼1.00,
[F(1,28)¼1.59, P¼0.22].
Fig. 6. Effect of the combined treatment with a sub-effective dose of Eugenia brasiliensis (0.1 mg/kg, p.o.) and phenylephrine (5 mg/kg, s.c.) or clonidine (0.06 mg/kg, i.p.) in
the TST (A and C) and in the open-ﬁeld test (B) and (D). Each column represents the mean7S.E.M (n¼8). nnPo0.01 compared with Eugenia brasiliensis group pre-treated
with vehicle. A) Pre-treatment [F(1,28)¼9.37, Po0.01], treatment [F(1,28)¼4.28, Po0.05] and pre-treatment x treatment interaction [F(1,28)¼5.78, Po0.05]; (B) Pre-
treatment [F(1,28)¼0.14, P¼0.71], treatment [F(1,28)¼1.47, P¼0.23] and pre-treatment x treatment interaction [F(1,28)¼0.24, P¼0.63]; (C) Pre-treatment [F(1,28)¼0.42,
P¼0.52], treatment [F(1,28)¼0.08, P¼0.78] and pre-treatment x treatment interaction [F(1,28)¼1.31, P¼0.26]; (D) Pre-treatment [F(1,28)¼0.02, P¼0.90], treatment
[F(1,28)¼0.76, P¼0.39] and pre-treatment x treatment interaction [F(1,28)¼0.17, P¼0.68].
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(Fig. 9C), without altering the locomotor activity in the open-ﬁeld test
(Fig. 9D).
The dopamine reuptake inhibitor bupropion, administered
at a sub-effective dose (1 mg/kg), exhibited an antidepressant-
like effect when combined with a sub-effective dose of Eugenia
brasiliensis in the TST (Fig. 9E), without causing alterations in the
locomotion in the open-ﬁeld test (Fig. 9F).4. Discussion
The TST is a well characterized behavioral model predictive of
antidepressant activity. In this test, animals are placed in an
inescapable situation and the antidepressant-like activity is
expressed by the decrease of immobility time, an effect that is
exhibited by conventional antidepressants (Cryan et al., 2005;
Steru et al., 1985). However, compounds that promote an increase
in locomotor activity of animals can produce a false positive
result in the TST. The effects of psychostimulant drugs can be
differentiated from antidepressants by the increase in locomotor
activity (Borsini et al., 1988). Thus, to rule out the possibility that
the reduction in immobility time produced by a given compound
in the TST is due to an increase in locomotor activity the animals
are submitted to the open-ﬁeld test (Rodrigues et al., 1996, 2002).
The results of this study show that among the ﬁve species
analyzed, Eugenia brasiliensis, Eugenia catharinae (1, 10 and 100
mg/kg), and Eugenia umbelliﬂora (10 and 100 mg/kg) reduced the
immobility time in the TST, without affecting the locomotor
activity in the open-ﬁeld test. Hence, the anti-immobility effect
of the extracts in the TST cannot be attributed to a psychostimulant
action. Eugenia uniﬂora, despite being used by the Guarani Indians
as a tonic stimulant and in folk medicine for the treatment of
symptoms related to depression and mood disorders, likely ner-
vousness, anxiety and irritation (Alonso, 1998; Alves et al., 2008;
Franco and Fontana, 2004; Greinger, 1996; Korbes, 1995), did not
produce a signiﬁcant antidepressant-like effect in the TST. More-
over, Eugenia beaurepaireana also produced no antidepressant-likeeffects. One possibility that could account for these negative results
is that doses higher than those employed in the present study
are necessary to cause an effect in the TST. Therefore, more studies
are necessary to rule out that Eugenia uniﬂora and Eugenia
beaurepaireana are devoid of any antidepressant-like effect. In this
work, Eugenia brasiliensis produced the most signiﬁcant results in
the TST compared with the other species analyzed. Moreover the
effective dose (1 mg/kg) can be considered a relatively low dose as
compared with effective doses of other plant extracts that show
antidepressant-like effects in the TST (Freitas et al., 2010; Lee et al.
2010; Machado et al., 2007, 2009). Therefore, we investigated the
possible mechanisms underlying the antidepressant-like action of
the extract of Eugenia brasiliensis in the TST.
It is important to mention that the chromatographic fractiona-
tion of Eugenia brasiliensis allowed the isolation of a-amyrin and
b-amyrin, betulin acid, 29-hydroxy-oleanolic, and the ﬂavonoids
quercetin, catechin and gallocatechin (Magina, 2008). Interesting
enough, some of these compounds were reported to cause anti-
depressant-like effects in behavioral models. Noteworthy, a- and
b-amyrin isolated from Protium heptaphyllum at doses of 2.5 and
5 mg/kg was shown to exert an antidepressant-like effect in the
FST (Arag~ao et al., 2006). In addition, quercetin also demonstrated
an antidepressant-like effect in the FST and exerted a selective
inhibitory activity on MAO-A (Bhutada et al., 2010; Chimenti et al.,
2006; Kaur et al., 2010; Saaby et al., 2009). Moreover, in vitro
studies demonstrated that catechin inhibited the uptake of ser-
otonin, norepinephrine and dopamine in cortex, striatum and
hippocampal synaptosomes (Rocha et al., 2007). It should also be
noted that another ﬂavonoid found in Eugenia brasiliensis, rutin, is
essential for the antidepressant-like activity of Hypericum perfor-
atum in the FST (Fischer et al., 2003; No¨ldner and Scho¨tz, 2002).
Also, rutin isolated from Schinus molle was shown to exert an
antidepressant-like effect in the TST (Machado et al., 2008). There-
fore, we may suppose that these compounds may be responsible
for the antidepressant-like effect obtained when mice were admi-
nistered with the extract of Eugenia brasiliensis.
The monoamines serotonin, norepinephrine and dopamine are
involved in the etiology of depression (Elhwuegi, 2004), and the
Fig. 7. Effect of pre-treatment with haloperidol (0.2 mg/kg, i.p.), SCH23390 (0.05 mg/kg, s.c.) or sulpiride (50 mg/kg, i.p.) in the effect of Eugenia brasiliensis (1 mg/kg, p.o.)
in the TST (A, C and E), and in the open-ﬁeld test (B, D and F). Each column represents the mean7S.E.M (n¼8). nnPo0.01 compared with the vehicle-treated control.
Po0.01 as compared with Eugenia brasiliensis group pre-treated with vehicle. (A) Pre-treatment [F(1,28)¼87.46, Po0.01], treatment [F(1,28)¼0.15, Po0.01] and pre-
treatment x treatment interaction [F(1,28)¼44.96, Po0.01]; (B) Pre-treatment [F(1,28)¼0.40, P¼0.53], treatment [F(1,28)¼2.61, P¼0.12] and pre-treatment x treatment
interaction [F(1,28)¼0.01, P¼0.92]; (C) Pre-treatment [F(1,28)¼6.27, Po0.05], treatment [F(1,28)¼6.95, Po0.05] and pre-treatment x treatment interaction
[F(1,28)¼6.20, Po0.05]; (D) Pre-treatment [F(1,28)¼0.12, P¼0.73], treatment [F(1,28)¼0.52, P¼0.47] and pre-treatment x treatment interaction [F(1,28)¼0.17,
P¼0.68]; (E) Pre-treatment [F(1,28)¼12.42, Po0.01], treatment [F(1,28)¼1.04, P¼0.32] and pre-treatment x treatment interaction [F(1,28)¼10.84, Po0.01]; (F) Pre-
treatment [F(1,28)¼0.89, P¼0.35], treatment [F(1,28)¼0.55, P¼0.46] and pre-treatment x treatment interaction [F(1,28)¼0.13, P¼0.72].
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on increasing the bioavailability of monoamines in the brain
(Blier, 2001; Brunello et al., 2002). Consistently, the vast majority
of drugs currently used to treat depression increase synaptic
levels of these monoamines (Risch and Nemeroff, 1992). More-
over, many plant extracts and compounds isolated from these
extracts exhibit antidepressant-like effects in the TST, at least
partly, by a modulation of the serotonergic system (Capra et al.,
2010; Dhingra and Kumar, 2008; Freitas et al., 2010; Machado
et al., 2007, 2008; Rodrigues et al., 2002).
The 5-HT1A receptors are directly related to the clinical effects
of antidepressants (Celada et al., 2004). These receptors are
located presynaptically on the soma and dendrites of 5-HT
neurons in the dorsal raphe, act as inhibitory autoreceptors and
decrease ﬁring rate and serotonin release (Shrestha et al., 2012).
Thus, compounds that block these receptors and prevent this
negative feedback might be effective to cause an antidepressant
response (Blier and Ward, 2003). The results of the present
study show that administration of WAY100635 (5-HT1A receptor
antagonist) has a synergistic effect with a sub-effective dose of
Eugenia brasiliensis (0.1 mg/kg), without affecting the locomotor
activity in the open-ﬁeld test. This result suggests that blocking
these receptors, increasing synaptic 5-HT levels, contributes tothe antidepressant-like effect of this extract. This result is in line
with the ﬁnding that the treatment with WAY100635 was able to
potentiate the effect of a sub-effective dose of ﬂuoxetine in the
FST (Da Rocha et al., 1997) as well as the extract from Tabebuia
avellanedae (Freitas et al., 2010) in the TST.
Further reinforcing the hypothesis that the antidepressant-like
effect of the extract of Eugenia brasiliensis is dependent on the
serotonergic system, the pre-treatment of mice with ketanserin,
a preferential 5-HT2A receptor antagonist, signiﬁcantly prevented
the reduction of immobility time induced by treatment of animals
with an effective dose of Eugenia brasiliensis (1 mg/kg, p.o.) in the
TST, which indicates that the effect of the extract is dependent
on an interaction with these receptors. Indeed, literature data
show that ketanserin is effective in reversing the antidepressant-
like effect of different compounds and extracts as agmatine
(Zomkowski et al., 2004) and lectin from Canavalia brasiliensis
(Barauna et al., 2006) in the FST and Tabebuia avellanedae, Schinus
mole and Rosmarinus ofﬁcinalis in the TST (Freitas et al., 2010;
Machado et al., 2007, 2009).
The 5-HT2 receptors are widely distributed throughout the brain,
being present in regions like the prefrontal cortex and hippocampus,
which are closely related to the etiology of depression (Ishihara and
Sasa, 2001; Krishnan et al., 1991; Nestler et al., 2002). It is suggested
Fig. 8. Effect of the combined treatment with a sub-effective dose of Eugenia brasiliensis (0.1 mg/kg, p.o.) and SKF38393 (0.1 mg/kg, s.c.) or apomorphine (0.5 mg/kg, i.p.) in
the TST (A) and (C) and in the open-ﬁeld test (B) and (D). Each column represents the mean7S.E.M (n¼8). nnPo0.01 compared with Eugenia brasiliensis group pre-treated
with vehicle. (A) Pre-treatment [F(1,28)¼21.38, Po0.01], treatment [F(1,28)¼8.68, Po0.01] and pre-treatment x treatment interaction [F(1,28)¼15.64, Po0.01]; (B) Pre-
treatment [F(1,28)¼0.33, P¼0.57], treatment [F(1,28)¼0.99, P¼0.33] and pre-treatment x treatment interaction [F(1,28)¼0.04, P¼0.84]; (C) Pre-treatment
[F(1,28)¼25.03, Po0.01], treatment [F(1,28)¼22.06, Po0.01] and pre-treatment x treatment interaction [F(1,28)¼19.11, Po0.01]; (D) Pre-treatment [F(1,28)¼2.48,
P¼0.13], treatment [F(1,28)¼0.30, P¼0.59] and pre-treatment x treatment interaction [F(1,28)¼1.77, P¼0.19].
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regulation of mood disorders (Celada et al., 2004; Hoyer et al., 1986).
In addition, it was shown that DOI, a preferential 5-HT2A receptor
agonist increases the effect of several antidepressant compounds
(Khisti and Chopde, 2000; Zomkowski et al., 2004).
To reinforce the idea of the involvement of serotonin in the
antidepressant-like effect of the extract of Eugenia brasiliensis,
a possible synergistic effect between the extract and ﬂuoxetine
(SSRI) in the TST was investigated. Fluoxetine, an antidepressant
that increases the availability of serotonin in the synaptic cleft,
when co-administered (p.o.) with the extract of Eugenia brasilien-
sis at sub-effective doses, potentiated the antidepressant-like
effect of the extract without causing alterations in the locomotion
of mice in the open-ﬁeld test. Thus, the antidepressant-like effect
of the extract appears to be dependent, at least in part, on the
increased levels of serotonin in the synaptic cleft.
The noradrenergic system is classically implicated in the
pathophysiology of depression and the mechanism of action of
antidepressants (Frazer, 2000; Nutt, 2006). Compounds or drugs
that affect noradrenergic neurotransmission, such as noradrena-
line reuptake inhibitors (SNRIs) or monoamine oxidase inhibitors
are used to treat depression (Pa´ez-Pereda, 2005). Preclinical
studies demonstrate that the a1 and a2-adrenoceptors are
involved in the antidepressant-like action of drugs or compounds
in animal models of depression (Danysz et al., 1986; Kitada et al.,
1983; Masuda et al., 2001). It was observed that the antidepres-
sant-like effect of desipramine (a tricyclic antidepressant with a
higher afﬁnity for the reuptake of norepinephrine) was prevented
by pre-treatment of mice with prazosin (an a1-adrenoceptor
antagonist) (Danysz et al., 1986). Furthermore, another study
demonstrated that the antidepressant-like effect of clonidine
(an a2-adrenoceptor agonist) in the FST was abolished by the
pre-treatment with yohimbine, an a2-adrenoceptor antagonist
(O’Neill et al., 2001).
The results of the present study show that pre-treatment with
prazosin (an a1-adrenoceptor antagonist) was able to prevent the
anti-immobility effect of Eugenia brasiliensis in the TST. Indeed,
studies have shown that activation of these receptors is essentialfor the effect of antidepressants that enhance noradrenergic
transmission (Brunello et al., 2002; Millan, 2004). In line with
this hypothesis, our results showed that the administration of
sub-effective doses of phenylephrine (an a1-adrenoceptor ago-
nist) with Eugenia brasiliensis produced a decrease in the
immobility time.
The pre-treatment of mice with yohimbine (an a2-adrenoceptor
antagonist) was also able to prevent the anti-immobility effect of
Eugenia brasiliensis, suggesting that a2-adrenoceptors are impli-
cated in the anti-immobility effect of the extract in the TST.
However, the administration of a sub-effective dose of clonidine
(an a2-adrenoceptor agonist) in combination with Eugenia brasi-
liensis was unable to reduce the immobility time in the TST. This
result do not conﬁrm the involvement of a2-adrenoceptors in the
antidepressant-like effect of Eugenia brasiliensis. Considering that
yohimbine (1 mg/kg) may act nonselectively as a 5-HT receptor
antagonist (Dwoskin et al., 1988), one plausible explanation for our
results is that yohimbine abolished the antidepressant-like effect of
Eugenia brasiliensis by acting at 5-HT receptors, and not directly by
the antagonism of a2-adrenoceptors.
Reinforcing the involvement of serotonergic and noradrenergic
systems in the antidepressant-like effect of the extract of Eugenia
brasiliensis, our study shows that imipramine, administered in
combination with the extract of Eugenia brasiliensis, at doses that
have no effect per se, caused a synergistic antidepressant-like
effect. Our data indicate that this effect was not due to any
locomotor alteration.
Besides the serotonergic and noradrenergic systems, the dopa-
minergic system is also implicated in mood regulation (D’Aquila
et al., 2000; Willner et al., 2005). Several evidence have indicated
that antidepressants with effects on the dopaminergic system are
effective for the treatment of depression (Papakostas, 2006).
Some studies have demonstrated the role of dopamine D1 and
D2 receptors in depression, since the antagonism of these recep-
tors prevents the effect of some agents with antidepressant-like
action in the FST and TST (Borsini et al., 1988; Hirano et al., 2007;
Machado et al., 2007; Yamada et al., 2004). Indeed, clinical studies
demonstrated that dopamine D2 receptor agonists are effective
Fig. 9. Effect of the administration of a sub-effective dose of the hydroalcoholic extract from Eugenia brasiliensis (0.1 mg/kg, p.o.) and sub-effective doses of ﬂuoxetine
(5 mg/kg, p.o.), imipramine (0.1 mg/kg, p.o) and bupropion (1 mg/kg, p.o.) in the TST (A, C and E) and in the open-ﬁeld test (B), (D) and (F). Each column represents the
mean7S.E.M (n¼8).nPo0.05 and nnPo0.01 as compared with the vehicle-treated group. (A) Pre-treatment [F(1,28)¼13.25, Po0.01], treatment [F(1,28)¼26.56, Po0.01]
and pre-treatment x treatment interaction [F(1,28)¼10.75, Po0.01]; (B) Pre-treatment [F(1,28)¼1.39, P¼0.25], treatment [F(1,28)¼0.07, P¼0.79] and pre-treatment x
treatment interaction [F(1,28)¼0.80, P¼0.38]; (C) Pre-treatment [F(1,28)¼6.42, Po0.05], treatment [F(1,28)¼5.08, Po0.05] and pre-treatment x treatment interaction
[F(1,28)¼4.65, Po0.05]; (D) Pre-treatment [F(1,28)¼0.46, P¼0.50], treatment [F(1,28)¼0.72, P¼0.40] and pre-treatment x treatment interaction [F(1,28)¼0.85, P¼0.36];
(E) Pre-treatment [F(1,28)¼11.63, Po0.01], treatment [F(1,28)¼15.62, Po0.01] and pre-treatment x treatment interaction [F(1,28)¼9.19, Po0.01]; (F) Pre-treatment
[F(1,28)¼0.14, P¼0.71], treatment [F(1,28)¼0.07; P¼0.79] and pre-treatment x treatment interaction [F(1,28)¼0.02, P¼0.90].
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Gerlach, 1981). The results of our study show that the dopami-
nergic system is involved in the antidepressant-like effect of
Eugenia brasiliensis, since the pre-treatment of animals with
haloperidol (a nonselective dopaminergic receptor antagonist),
SCH23390 (a dopamine D1 receptor antagonist) and sulpiride
(a dopamine D2 receptor antagonist) prevented the antidepres-
sant-like effect caused by administration of Eugenia brasiliensis in
the TST. Moreover, reinforcing the participation of the dopami-
nergic system in the antidepressant-like effect of Eugenia brasi-
liensis, the treatment with sub-effective doses of SKF38393
(0.1 mg/kg, s.c., a dopamine D1 receptor agonist) or apomorphine
(0.5 mg/kg, i.p., a dopamine D2 receptor agonist) with Eugenia
brasiliensis was able to produce an antidepressant-like effect.
Interestingly, bupropion, an atypical antidepressant that is a
potent inhibitor of dopamine uptake, when co-administered
(p.o.) with the extract of Eugenia brasiliensis, at doses that have
no effect per se, potentiates the antidepressant-like effect of the
extract, without affecting the locomotor activity of animals.
Considering that treatment of depression with conventional
antidepressants produces several side effects (Brunello et al.,
2002) that may reduce the adhesion of patients to treatment
(MacGillivray et al., 2003; Sleath et al., 2003), there is a need todevelop strategies for antidepressant treatment with fewer side
effects. Therefore, the results obtained with the co-administration
of hydroalcoholic extract of Eugenia brasiliensis with the antide-
pressants ﬂuoxetine, imipramine and bupropion suggest that this
extract could be helpful for the improvement of the conventional
pharmacotherapy (decreasing the doses of antidepressants pre-
scribed and consequently the side effects). Further studies are
necessary to conﬁrm this hypothesis.5. Conclusions
The present study demonstrated that Eugenia brasiliensis,
Eugenia catharinae and Eugenia umbelliﬂora exert an antidepres-
sant-like effect in the TST. Our ﬁndings indicate that the hydro-
alcoholic extract of Eugenia brasiliensis has this effect mediated by
serotonergic, noradrenergic and dopaminergic systems. Further-
more, this extract can produce a synergistic antidepressant-like
effect with the antidepressants ﬂuoxetine, imipramine and bupro-
pion, suggesting that this extract may improve the effectiveness
of these antidepressants. Altogether, the results suggest that
Eugenia brasiliensis may have potential therapeutic value for the
management of depression.
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